other material
confidence high
sentiment positive
materiality 0.60
Immix Biopharma reports IMX-110 50% response rate in STS mouse study, beating standard of care
Immix Biopharma, Inc.
- IMX-110 as monotherapy achieved 50% response rate in first-line-therapy-resistant STS mouse study, vs 0% for doxorubicin.
- Study assessed by RECIST 1.1 criteria after one cycle; funded by Immix and conducted by major STS oncology center.
- IMX-110 has FDA orphan drug designation for STS and rare pediatric disease designation for rhabdomyosarcoma.
- Global STS market estimated $2.9B in 2019, projected to reach $6.5B by 2030.
- Prior clinical data showed median PFS of 4 months with zero drug-related severe adverse events in heavily pretreated patients.